NHS trials AI and genomics for safer blood matching

TL;DR:

  • NHS Blood and Transplant has launched a 12-month study of bloodMatcher, which uses AI and genomic data to match blood more precisely.
  • It targets sickle cell patients, around 17% of whom develop antibodies that complicate future transfusions.
  • Around 40 patients at UCLH will take part, with results intended to inform a larger multi-centre trial.

NHS Blood and Transplant has begun evaluating an AI tool designed to make blood transfusions safer for people with sickle cell disorder, one of a growing number of concrete clinical uses of AI in the UK health service. The bloodMatcher algorithm combines genomic data with AI to identify more closely matched donations and make better use of rare blood units.

Precision matching for a high-risk group

The problem is specific and serious. While NHSBT routinely matches major blood groups, sickle cell patients who need regular transfusions are prone to alloimmunisation — developing antibodies against minor blood groups — which can trigger reactions and make future transfusions riskier. NHSBT estimates around 17% of adults with the disorder develop such antibodies. The 12-month feasibility study uses DNA-based genotyping to test donors and recipients across a far wider range of markers than the four core groups used in current practice, with the algorithm folding those minor groups into its recommendations.

Clinical lead Dr Sara Trompeter said the tool would select units “in a faster, far more advanced way”, reducing the risk of severe reactions and cutting waste of rare units. Around 40 adult patients at University College London Hospitals will take part, with all existing safety procedures retained and an added review by a clinical scientist. The work is run with UCLH and the NIHR, with funding from the NIHR Artificial Intelligence Programme.

Looking forward

The study is a measured example of AI in medicine — narrow, evidence-led and safety-wrapped — in contrast to the sweeping productivity claims attached to the 505,000-staff Copilot rollout announced the same day. If results hold, researchers hope to support a larger multi-centre trial and wider NHS adoption of genomically informed matching. For UK patients, the payoff is practical: fewer complications and better long-term care for an underserved group, with the rigour that clinical AI demands.

Share this article